Last reviewed · How we verify
Fibrogammin
Fibrogammin, marketed by Christian Haslinger, is a therapeutic agent with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current marketed status, providing a competitive edge over pre-market competitors. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Fibrogammin |
|---|---|
| Also known as | Factor XIII |
| Sponsor | Christian Haslinger |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Disorders of the Acute Phase Response Following Trauma and Invasive Surgery (NA)
- Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children (PHASE3)
- Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke (NA)
- Venous Thromboembolism in Myotonic Dystrophy Type 1 (NA)
- Haemodialysis Alters Hypercoagulability of Blood in Dialysis Patients
- Perioperative Treatment With Tranexamic Acid in Melanoma (PHASE3)
- SWIFT - SWIss Factor XIII Trial in PPH (PHASE4)
- Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fibrogammin CI brief — competitive landscape report
- Fibrogammin updates RSS · CI watch RSS
- Christian Haslinger portfolio CI